Seeking Alpha

AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall...

AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall Street analysts, saying the drugmaker needs a "transformational deal" to return it to profit growth. A deal for Shire (SHPG +0.2%) or Forest Labs (FRX +0.7%) would rival its's $15B acquisition of MedImmune in 2007. SHPG could help fill the gap with patent-protected medicines for rare diseases and leading ADD therapies, says Kepler Capital Markets, while FRX's lung treatment would bolster the company's respiratory business.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|